NPRA Banner

               
Product Search   QUEST3+ System   Enquiries   Sitemap  

Madonna® (levonorgestrel): Levonorgestrel-containing emergency hormonal contraception ─ New advice on interactions with hepatic enzyme inducers and contraceptive efficacy

User Rating: 3 / 5

Star ActiveStar ActiveStar ActiveStar InactiveStar Inactive
 

Date: 5 April 2017

 

Description:

Concomitant use of liver enzyme inducers—mainly inducers of CYP3A4 enzymes—increases the metabolism of levonorgestrel. This results in a decrease in plasma levonorgestrel levels, which may reduce the contraceptive efficacy of levonorgestrel-containing emergency hormonal contraceptives. Women seeking emergency contraception who have used an enzyme-inducing medicine within the last 4 weeks, are advised to use a non-hormonal emergency contraceptive, i.e. a copper intrauterine device (Cu-IUD). If this is not an option, they should be advised to double the usual dose of levonorgestrel from 1.5 mg to 3 mg to compensate for the reduction in plasma levonorgestrel levels. The information on the medicine’s outer carton and package insert will be revised to include the new dosing instructions for this category of women. A Direct Healthcare Professional Communication (DHPC) has been issued by Medispec (M) Sdn. Bhd. in agreement with NPRA to highlight this updated information.

 

 

 

National Pharmaceutical Regulatory Agency (NPRA)

Lot 36, Jalan Universiti (Jalan Prof Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.

  • Phone: +603-7883 5400

 

 

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Site Last Modified

  • Last Modified: Thursday 10 October 2024, 16:28:58.

Search

Main Menu English